Bendamustine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Bendamustine
- Pharmacist Assessment Report
- Bendamustine: alkylating cytotoxic agent → mantle cell lymphoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Bendamustine: alkylating cytotoxic agent → mantle cell lymphoma
One-Sentence Summary
Bendamustine is an alkylating chemotherapy drug that damages DNA in B-cell cancers and is marketed in Canada under 11 valid licences. The TxGNN model predicts it may be effective for mantle cell lymphoma, with a score of 0.9963. The data compiled for this report include 40 clinical trials and 20 publications on this disease, including large randomized Phase 3 studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Mantle cell lymphoma |
| TxGNN Prediction Score | 0.9963 |
| Evidence Level | L1 |
| Canada Market Status | Marketed (marketed DINs: 11 of 11) |
| Number of DINs | 11 (marketed: 11) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the compiled data. Bendamustine is generally described as an alkylating agent with purine-analog-like properties: it cross-links DNA and triggers apoptosis in B-cell malignancies.
Mantle cell lymphoma is a mature B-cell neoplasm, biologically close to the B-cell lymphomas in which bendamustine is already used, so the cytotoxic mechanism plausibly applies directly. Bendamustine plus rituximab is already an established backbone regimen in mantle cell lymphoma, and it serves as the comparator or backbone in several large Phase 3 trials.
Clinical Trial Evidence
Of the 40 trials listed, the most relevant are shown below (selected from those directly addressing mantle cell lymphoma).
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00991211 | Phase 3 | Completed | 549 | First-line bendamustine + rituximab vs CHOP + rituximab in indolent lymphoma and MCL (non-inferiority on PFS) |
| NCT00877006 | Phase 3 | Completed | 447 | BRIGHT: bendamustine + rituximab vs R-CHOP/R-CVP in first-line indolent NHL or MCL |
| NCT01776840 | Phase 3 | Completed | 523 | Ibrutinib added to bendamustine + rituximab in newly diagnosed MCL, age 65+ |
| NCT02972840 | Phase 3 | Active, not recruiting | 635 | Acalabrutinib + bendamustine + rituximab vs placebo + BR in untreated MCL |
| NCT06363994 | Phase 3 | Recruiting | 476 | Orelabrutinib + BR vs BR in treatment-naive MCL |
| NCT06084936 | Phase 3 | Recruiting | 182 | Glofitamab vs investigator’s choice (BR or R-lenalidomide) in relapsed/refractory MCL |
| NCT00891839 | Phase 2 | Completed | 45 | Bendamustine + rituximab in relapsed/refractory MCL |
| NCT00612183 | Phase 2 | Completed | 56 | Bendamustine (SyB L-0501) in indolent B-cell NHL or MCL |
| NCT03834688 | Phase 2 | Completed | 33 | Venetoclax + bendamustine + rituximab in untreated MCL, age over 60 |
| NCT01662050 | Phase 2 | Completed | 57 | Age-adjusted rituximab-bendamustine-cytarabine in older MCL patients |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23433739 | 2013 | RCT | Lancet | Bendamustine + rituximab vs R-CHOP as first-line treatment in indolent and mantle-cell lymphomas (Phase 3 non-inferiority) |
| 30811293 | 2019 | RCT | J Clin Oncol | BRIGHT 5-year follow-up of BR vs R-CHOP/R-CVP |
| 35657079 | 2022 | RCT | N Engl J Med | Ibrutinib added to BR in untreated MCL |
| 40311141 | 2025 | RCT | J Clin Oncol | Acalabrutinib added to BR in untreated MCL |
| 41052510 | 2025 | RCT | Lancet | ENRICH: ibrutinib-rituximab vs immunochemotherapy (R-CHOP or BR) in older untreated MCL |
| 32985902 | 2021 | RCT | Future Oncol | Phase 3 design of zanubrutinib + rituximab vs BR in transplant-ineligible MCL |
| 32126141 | 2020 | Cohort | Blood Adv | Rituximab/bendamustine and rituximab/cytarabine induction before transplant in MCL |
| 41132246 | 2025 | Guideline | HemaSphere | EHA-EU MCL network guidelines for diagnosis and treatment |
| 40975105 | 2025 | Phase 2 | Lancet Haematol | Rituximab, bendamustine, cytarabine followed by venetoclax in older high-risk MCL |
| 26755518 | 2016 | Review | J Clin Oncol | Mantle cell lymphoma review, including the role of bendamustine in older patients |
Canada Market Information
Bendamustine has 11 valid single-ingredient licences in Canada. The local records do not include dosage forms or approved-indication text. Main authorizations:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02392569 | TREANDA | Not recorded | Not recorded |
| 02392550 | TREANDA | Not recorded | Not recorded |
| 02524309 | BENVYON | Not recorded | Not recorded |
| 02496895 | NAT-BENDAMUSTINE | Not recorded | Not recorded |
| 02496852 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | Not recorded | Not recorded |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent) |
| Myelosuppression Risk | High. Neutropenia, thrombocytopenia and anaemia are listed among the compiled contraindicated conditions. |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | Complete blood count with differential, liver and renal function |
| Handling Protection | Follow cytotoxic drug handling regulations |
Please refer to the package insert warnings and precautions for full details.
Safety Considerations
- Conditions flagged as contraindications in the compiled data: liver failure, kidney disease, liver disease, gallbladder disease, pyoureter, thrombocytopenia, neutropenia, agranulocytosis, anaemia and macrocytic anaemia. These are not label text and should be checked against the package insert.
- Drug Interactions: 100 interactions were recorded. Major-level interactions include deferiprone and samarium (153Sm) lexidronam, both of which carry added bone-marrow suppression concerns. Moderate-level examples include omeprazole, esomeprazole, cimetidine, caffeine, mercaptopurine and ticlopidine.
Please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several completed randomized Phase 3 trials (including BRIGHT and the Lancet non-inferiority study) and many Phase 2 studies directly study bendamustine-based therapy in mantle cell lymphoma, and the mechanism is plausible. Haematological toxicity and organ-function limits require guardrails.
To proceed, the following is needed:
- Review of Health Canada package insert warnings and contraindications, and of the approved indication text
- Detailed mechanism-of-action data
- Confirmation of whether mantle cell lymphoma is within the currently licensed indications in Canada
- A monitoring plan for myelosuppression, infection risk and renal or hepatic impairment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.